Location History:
- Nankang, TW (2013)
- Taipei, TW (2008 - 2014)
- Bethesda, MD (US) (2010 - 2017)
Company Filing History:
Years Active: 2008-2017
Title: Chi-Ming Liang: Innovator in Cancer Research
Introduction
Chi-Ming Liang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer research, holding a total of 8 patents. His work focuses on innovative methods to suppress cancer metastasis, which is a leading cause of treatment failure and mortality in cancer patients.
Latest Patents
One of his latest patents involves the suppression of cancer metastasis through the use of fibrillar proteins. This method demonstrates that tumor cell invasion and migration can be significantly inhibited after treatment with fibrillar proteins such as rVP1, F-HSA, and F-BSA in vitro. Furthermore, rVP1 has shown the ability to significantly suppress murine and human breast cancer metastasis, as well as human prostate and ovarian cancer metastasis in vivo. Another notable patent is related to anti-tumor fibrillar human serum albumin methods and compositions, which have proven effective in treating various types of cancers. These methods disclose the use of fibrillar human serum albumin as a medicament for subjects diagnosed with cancer.
Career Highlights
Chi-Ming Liang is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has garnered attention for its potential impact on cancer treatment and patient outcomes.
Collaborations
He has collaborated with notable colleagues such as Shu-Mei Liang and Jei-Ming Peng, contributing to the advancement of cancer research through shared expertise and innovative ideas.
Conclusion
Chi-Ming Liang's contributions to cancer research through his patents and collaborations highlight his commitment to improving treatment options for cancer patients. His innovative approaches continue to pave the way for advancements in the medical field.